Research Antibody Reproducibility

It’s All About Validation

The reproducibility of scientific studies has become a major issue, leading to a lack of trust in scientific results from the academic and pharmaceutical research communities. While issues around reproducibility have been discussed for years, calls for action have been infrequent and half-hearted. Beginning in about 2012, a number of articles, letters, and editorials started appearing in Nature, Science and other publications, with some going so far as to call this a “reproducibility crisis.”

Read more: Research Antibody Reproducibility

The lack of consistent research on antibody validation has contributed to the scientific reproducibility
crisis.

Source: genengnews

Fifty Biotech and Biopharma Recruiters in the Lists.

Who They Know Can Help You Land a Job in the Industry

In Deloitte’s “2016 U.S. Life Sciences Industry Outlook” released in January, Greg Reh, the firm’s U.S. and Global Life Sciences sector leader, offered a somewhat encouraging assessment of employment prospects this year: “Despite current economic, political, technological, and social challenges, life sciences companies worldwide should see enough long-term growth opportunities to feel cautiously optimistic about 2016.”

Three such opportunities were identified by recruiting firm Smith Hanley Associates earlier this year: One was candidate movement to smaller biopharmas, which the firm said leads to higher base salaries as companies scramble to offset the loss of long-term incentives given by big pharma. Mergers and acquisitions create jobs for candidates willing to relocate, whereas the growth of big data adds positions for in-house data scientists but also results in project outsourcing to vendors that creates new markets and innovations, Smith Hanley added.

All those trends should mean more work for biopharma recruiters, who match employers with job candidates in significant portions of the industry.

Read more: Fifty Biotech and Biopharma Recruiters in the Lists.

The workload of recruiters should increase this year since biotech and other life sciences employers
worldwide “should see enough long-term growth opportunities to feel cautiously optimistic about
2016,” according to Deloitte Consulting.

Source:  auremar/Fotolia